Share on Google Plus Share on Twitter Share on Facebook Share on LinkedIn Share on PInterest Share on Fark! Share on Reddit Share on StumbleUpon Tell A Friend

Printer Friendly Page Save As Favorite View Favorites (# of views)   1 comment
OpEdNews Op Eds

Thirty years of HIV epidemic in India: From despair to hope

      (Page 1 of 2 pages)
Related Topic(s): ; ; ; ; , Add Tags Add to My Group(s)

Must Read 1   Valuable 1  
View Ratings | Rate It

opednews.com Headlined to H4 10/30/15

Author 91838
Become a Fan
  (2 fans)
- Advertisement -
Shobha Shukla, Citizen News Service - CNS

30 years of HIV in India: Long way to go still?
(Image by CNS (Citizen News Service))
  Permission   Details   DMCA


- Advertisement -
Video is online at: https://www.youtube.com/watch?v=5N3EWRoXhzM

It is almost 30 years since the first case of HIV infection was detected in India in Chennai in 1986. In a recent webinar organized by Citizen News Service (CNS), Dr R R Gangakhedkar, Director-in-charge, National AIDS Research Institute, Pune (Indian Council of Medical Research), presented a vivid picture of India's tumultuous journey in its fight against this dreaded disease.

Going down memory lane, Dr Gangakhedkar recalled that India took almost 6 years (after the 1st HIV patient was diagnosed) to finally wake up to the realization of the imminent threat of HIV/AIDS, and thus was born the National AIDS Control Programme in 1991-92. Initially it offered treatment only for sexually transmitted infections (STIs) and opportunistic infections (OIs) arising out of HIV. The developed world was, at that time, already providing sequential mono therapy for the disease. 1994 proved to be another landmark year for the West, when prevention of mother to child transmission (PMTCT) became possible with AZT (generic name zidovudine, Retrovir). Also, protease inhibitors led to the evolution of the 3 drugs combination anti retroviral therapy (ART).

From despondency to action

- Advertisement -

The first anti-HIV drug, zidovudine was marketed in India in 1995 but the cost was prohibitively high. It was only in 2000 that generic pharmaceutical companies started manufacturing the drug and prices came down drastically. At that time the feasibility studies for PMTCT, that began in 1998-99, were already over. The government's PMTCT programme started in 2001--with a private pharmaceutical company CIPLA providing single dose Nevirapine free of cost to as many women and children as possible across the country. Then free ART was rolled out in 2004.

Current status

Today, government programme uses the CD4 cell count cut-off 210, and this is much better than that in many other countries, says Gangakhedkar.

The new WHO guideline

Recent results of the START, TEMPRANO and HPTN 052 studies, as well as various pre exposure prophylaxis (PrEP) studies have led to new approaches for treatment and prevention. The latest WHO HIV guideline makes available two key recommendations that were developed during the revision process in 2015. Firstly, ART should be initiated in all PLHIV irrespective of their CD4 cell count. Secondly, the use of daily oral PrEP is recommended as a prevention choice for people at substantial risk of HIV infection as part of combination prevention approaches.

Can India implement these recommendations?

In India, estimated ART coverage among the 21 lakh people living with HIV (PLHIV) is 38%, with close to 8 lakhs PLHIV alive and on ART--768840 on 1st line and 8500 on 2nd line ART. Almost 50% of those who are infected never came in contact with the government programme. If India takes evidence into account and begins to provide ART to the remaining 62% PLHIV, regardless of CD4, then public health outcomes are likely to be enormous -- including, but not limited to, quality of life and care, and reducing the rate of new infections as well.

- Advertisement -

However, despite having a massive infrastructure for provision of free ART related services --516 ART centres, over 976 Link ART centres, 5100 integrated counselling & testing centres, 350 care & support centres--Gangakhedkar lists some of the key challenges that will have to be overcome to adopt the 'treat all' approach. These are:

Strengthening existing ART centres to ensure that the number of PLHIV per healthcare provider is manageably small in order to offer quality services

Enhancing coverage to key population groups of sex workers, men who have sex with men, and injecting drug users

Enhancing coverage by ensuring access to testing and treatment services in low prevalence states

Next Page  1  |  2

 

- Advertisement -

Must Read 1   Valuable 1  
View Ratings | Rate It

Citizen News Service (CNS) specializes in in-depth and rights-based, health and science journalism. For more information, please contact: www.citizen-news.org or @cns_health or www.facebook.com/cns.page

Share on Google Plus Submit to Twitter Add this Page to Facebook! Share on LinkedIn Pin It! Add this Page to Fark! Submit to Reddit Submit to Stumble Upon



Go To Commenting
/* The Petition Site */
The views expressed in this article are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.

Writers Guidelines

Contact AuthorContact Author Contact EditorContact Editor Author PageView Authors' Articles
Related Topic(s): ; ; ; ; , Add Tags
- Advertisement -

Most Popular Articles by this Author:     (View All Most Popular Articles by this Author)

Management of respiratory diseases beyond drugs: Pulmonary Rehabilitation

New funding boosts research for controlling TB, malaria, dengue and leishmaniasis

Oxygen therapy is like a prescription drug: Use it rationally

Progress made but work remains on firewalling health policy from tobacco industry

World Health Day: No substitute to healthy mind

Nepal leading tobacco control in South Asia: Will it spiral domino effect on other nations?